Etanercept in the treatment of macrophage activation syndrome.
Etanercept in the treatment of macrophage activation syndrome.
复制标题
DOI：
--
复制
发表时间：
2001-09
期刊：
影响因子：
--
通讯作者：
S. Prahalad;K. Bove;D. Dickens;D. Lovell;A. Grom
中科院分区：
文献类型：
--
作者：
S. Prahalad;K. Bove;D. Dickens;D. Lovell;A. Grom
巨噬细胞激活综合征（MAS）是一种公认的系统性幼年类风湿性关节炎（sJRA）的并发症，与显著的发病率和死亡率相关。巨噬细胞-淋巴细胞相互作用失调导致高度活化的巨噬细胞不受控制的增殖和包括肿瘤坏死因子- α (tnf - α)在内的促炎细胞因子的大量释放似乎是该综合征发病机制的核心。到目前为止，主要的治疗方法是皮质类固醇和环孢素a。我们描述了一个患者与MAS和sJRA成功治疗抗肿瘤坏死因子的药物依那西普。该患者的结果提示依那西普可能是治疗MAS的有效药物。
Macrophage activation syndrome (MAS), a recognized complication of systemic juvenile rheumatoid arthritis (sJRA), has been associated with significant morbidity and mortality. Dysregulation of macrophage-lymphocyte interactions leading to uncontrolled proliferation of highly activated macrophages and massive release of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) appears to be central to the pathogenesis of this syndrome. Until now the mainstay of therapy has been corticosteroids and cyclosporin A. We describe a patient with MAS and sJRA successfully treated with the anti-TNF agent etanercept. The outcome in this patient suggests etanercept might be an effective therapeutic agent in MAS.